{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:40:22Z","timestamp":1780044022272,"version":"3.53.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P50AR070604"],"award-info":[{"award-number":["P50AR070604"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015461","name":"Audentes Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtm.2023.101144","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T20:33:05Z","timestamp":1698352385000},"page":"101144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Persistence of exon 2 skipping and dystrophin expression at 18\u00a0months after U7snRNA-mediated therapy in the Dup2 mouse model"],"prefix":"10.1016","volume":"31","author":[{"given":"Liubov V.","family":"Gushchina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne J.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob W.","family":"Lay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"Rohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Frair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Wein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.101144_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2023.101144_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajmg.a.30617","article-title":"Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort","volume":"134","author":"Dent","year":"2005","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.omtm.2023.101144_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2023.101144_bib4","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/humu.20367","article-title":"Duplications in the DMD gene","volume":"27","author":"White","year":"2006","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtm.2023.101144_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2023.101144_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne muscular dystrophy","volume":"56","author":"Anwar","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.omtm.2023.101144_bib7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2023.101144_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2023.101144_bib9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nm.3628","article-title":"Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice","volume":"20","author":"Wein","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101144_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.nmd.2009.08.010","article-title":"DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy","volume":"19","author":"Flanigan","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2023.101144_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/humu.20913","article-title":"DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6","volume":"30","author":"Gurvich","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtm.2023.101144_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.omtm.2021.03.014","article-title":"Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping","volume":"21","author":"Simmons","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101144_bib13","first-page":"1346","article-title":"Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications","volume":"32","author":"Wein","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101144_bib14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1089\/hum.2020.286","article-title":"Lack of toxicity in non-human primates receiving clinically relevant doses of an AAV9.U7snRNA vector designed to induce DMD exon 2 skipping","volume":"32","author":"Gushchina","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101144_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omtm.2022.07.005","article-title":"Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse","volume":"26","author":"Wein","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101144_bib16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.nmd.2015.08.005","article-title":"The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development","volume":"25","author":"Vulin","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2023.101144_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.omtn.2022.10.025","article-title":"Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy","volume":"30","author":"Gushchina","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101144_bib18","doi-asserted-by":"crossref","first-page":"e730","DOI":"10.1212\/WNL.0000000000013246","article-title":"Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications","volume":"98","author":"Zambon","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2023.101144_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-G","article-title":"The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy","volume":"26","author":"Nigro","year":"1990","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.omtm.2023.101144_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/nat.2011.0306","article-title":"Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity","volume":"21","author":"Malerba","year":"2011","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtm.2023.101144_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/hum.2019.255","article-title":"Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy","volume":"32","author":"Potter","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101144_bib22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.omtm.2020.03.011","article-title":"Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice","volume":"17","author":"Forand","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101144_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","article-title":"A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Gan","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101144_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2023.04.017","article-title":"Presidential Symposium and Presentation of Top Abstracts","volume":"31","author":"Megan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101144_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ymthe.2004.09.013","article-title":"Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury","volume":"11","author":"Liu","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101144_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2023.101144_bib27","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2023.101144_bib28","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101144_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.101144_bib30","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human Immune Responses to Adeno-Associated Virus (AAV) Vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.101144_bib31","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101144_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.omtm.2023.101144_bib33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.omtn.2023.05.014","article-title":"Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy","volume":"32","author":"Srivastava","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101144_bib34","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1152\/japplphysiol.01425.2010","article-title":"The passive mechanical properties of the extensor digitorum longus muscle are compromised in 2- to 20-mo-old mdx mice","volume":"110","author":"Hakim","year":"2011","journal-title":"J.\u00a0Appl. Physiol."},{"key":"10.1016\/j.omtm.2023.101144_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-61737-982-6_5","article-title":"Monitoring murine skeletal muscle function for muscle gene therapy","volume":"709","author":"Hakim","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtm.2023.101144_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jmor.1052210207","article-title":"Relationship between muscle fiber types and sizes and muscle architectural properties in the mouse hindlimb","volume":"221","author":"Burkholder","year":"1994","journal-title":"J.\u00a0Morphol."},{"key":"10.1016\/j.omtm.2023.101144_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ymthe.2017.02.013","article-title":"Systemic AAV-Mediated beta-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice","volume":"25","author":"Pozsgai","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101144_bib38","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2110","article-title":"Virus Binding and Internalization Assay for Adeno-associated Virus","volume":"7","author":"Berry","year":"2017","journal-title":"Bio. Protoc."},{"key":"10.1016\/j.omtm.2023.101144_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12785","article-title":"Automated immunofluorescence analysis for sensitive and precise dystrophin quantification in muscle biopsies","volume":"48","author":"Vetter","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T15:21:19Z","timestamp":1762615279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123001833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":39,"alternative-id":["S2329050123001833"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101144","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of exon 2 skipping and dystrophin expression at 18\u00a0months after U7snRNA-mediated therapy in the Dup2 mouse model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101144"}}